{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:36:26Z","timestamp":1791905786593,"version":"4.3.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T00:00:00Z","timestamp":1604275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T00:00:00Z","timestamp":1604275200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1038\/s41409-020-01082-z","type":"journal-article","created":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T13:03:09Z","timestamp":1604322189000},"page":"853-862","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Efficacy of prophylactic letermovir for cytomegalovirus reactivation in hematopoietic cell transplantation: a multicenter real-world data"],"prefix":"10.1038","volume":"56","author":[{"given":"Yasuo","family":"Mori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiaki","family":"Jinnouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuto","family":"Takenaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takatoshi","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuro","family":"Kuriyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Kadowaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Odawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Kohno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goichi","family":"Yoshimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Takase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideho","family":"Henzan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikiyo","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiko","family":"Kamimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuju","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Eto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Nagafuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Akashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6533-1594","authenticated-orcid":false,"given":"Toshihiro","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,2]]},"reference":[{"key":"1082_CR1","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/cid\/ciu364","volume":"59","author":"P Ljungman","year":"2014","unstructured":"Ljungman P, Brand R, Hoek J, de la Camara R, Cordonnier C, Einsele H, et al. Donor cytomegalovirus status influences the outcome of allogeneic stem cell transplant: a study by the European Group for Blood and Marrow Transplantation. Clin Infect Dis. 2014;59:473\u201381.","journal-title":"Clin Infect Dis."},{"key":"1082_CR2","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1182\/blood-2015-11-679639","volume":"127","author":"P Teira","year":"2016","unstructured":"Teira P, Battiwalla M, Ramanathan M, Barrett AJ, Ahn KW, Chen M, et al. Early cytomegalovirus reactivation remains associated with increased transplant related mortality in the current era: a CIBMTR analysis. Blood. 2016;127:2427\u201338.","journal-title":"Blood."},{"key":"1082_CR3","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/j.bbmt.2015.07.019","volume":"21","author":"K Takenaka","year":"2015","unstructured":"Takenaka K, Nishida T, Asano-Mori Y, Oshima K, Ohashi K, Mori T, et al. Cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation is associated with a reduced risk of relapse in patients with acute myeloid leukemia who survived to day 100 after transplantation: the Japan Society for Hematopoietic Cell Transplantation transplantation-related complication working group. Biol Blood Marrow Transplant. 2015;21:2008\u201316.","journal-title":"Biol Blood Marrow Transplant."},{"key":"1082_CR4","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1182\/blood.V88.10.4063.bloodjournal88104063","volume":"88","author":"M Boeckh","year":"1996","unstructured":"Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood. 1996;88:4063\u201371.","journal-title":"Blood."},{"key":"1082_CR5","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/sj.bmt.1704232","volume":"32","author":"M Yanada","year":"2003","unstructured":"Yanada M, Yamamoto K, Emi N, Naoe T, Suzuki R, Taji H, et al. Cytomegalovirus antigenemia and outcome of patients treated with pre-emptive ganciclovir: retrospective analysis of 241 consecutive patients undergoing allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2003;32:801\u20137.","journal-title":"Bone Marrow Transplant."},{"key":"1082_CR6","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s12185-012-1087-9","volume":"96","author":"K Takenaka","year":"2012","unstructured":"Takenaka K, Nagafuji K, Takase K, Kamimura T, Mori Y, Ito Y, et al. Initial low-dose valganciclovir as a preemptive therapy is effective for cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients. Int J Hematol. 2012;96:94\u2013100.","journal-title":"Int J Hematol."},{"key":"1082_CR7","doi-asserted-by":"crossref","first-page":"5711","DOI":"10.1182\/blood-2008-10-143560","volume":"113","author":"M Boeckh","year":"2009","unstructured":"Boeckh M, Ljungman P. How I treat cytomegalovirus in hematopoietic cell transplant recipients. Blood. 2009;113:5711\u20139.","journal-title":"Blood."},{"key":"1082_CR8","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/S2352-3026(15)00289-6","volume":"3","author":"ML Green","year":"2016","unstructured":"Green ML, Leisenring W, Xie H, Mast TC, Cui Y, Sandmaier BM, et al. Cytomegalovirus viral load and mortality after hematopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study. Lancet Haematol. 2016;3:e119\u201327.","journal-title":"Lancet Haematol."},{"key":"1082_CR9","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1172\/JCI45449","volume":"121","author":"M Boeckh","year":"2011","unstructured":"Boeckh M, Geballe AP. Cytomegalovirus: pathogen, paradigm, and puzzle. J Clin Investig. 2011;121:1673\u201380.","journal-title":"J Clin Investig."},{"key":"1082_CR10","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1128\/JVI.01955-12","volume":"87","author":"EM Borst","year":"2013","unstructured":"Borst EM, Kleine-Albers J, Gabaev I, Babic M, Wagner K, Binz A, et al. The human cytomegalovirus UL51 protein is essential for viral genome cleavage-packaging and interacts with the terminase subunits pUL56 and pUL89. J Virol. 2013;87:1720\u201332.","journal-title":"J Virol."},{"key":"1082_CR11","doi-asserted-by":"crossref","first-page":"10884","DOI":"10.1128\/JVI.05265-11","volume":"85","author":"T Goldner","year":"2011","unstructured":"Goldner T, Hewlett G, Ettischer N, Ruebsamen-Schaeff H, Zimmermann H, Lischka P. The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase. J Virol. 2011;85:10884\u201393.","journal-title":"J Virol."},{"key":"1082_CR12","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","volume":"377","author":"FM Marty","year":"2017","unstructured":"Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017;377:2433\u201344.","journal-title":"N Engl J Med."},{"key":"1082_CR13","doi-asserted-by":"crossref","first-page":"e13187","DOI":"10.1111\/tid.13187","volume":"21","author":"A Lin","year":"2019","unstructured":"Lin A, Maloy M, Su Y, Bhatt V, DeRespiris L, Griffin M et al. Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: Real-world experience. Transpl Infect Dis. 2019;21:e13187.","journal-title":"Transpl Infect Dis"},{"key":"1082_CR14","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/s41409-019-0730-y","volume":"55","author":"P Sharma","year":"2020","unstructured":"Sharma P, Gakhar N, MacDonald J, Abidi MZ, Benamu E, Bajrovic V, et al. Letermovir prophylaxis through day 100 post transplant is safe and effective compared with alternative CMV prophylaxis strategies following adult cord blood and haploidentical cord blood transplantation. Bone Marrow Transplant. 2020;55:780\u20136.","journal-title":"Bone Marrow Transplant."},{"key":"1082_CR15","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1182\/bloodadvances.2018016493","volume":"2","author":"K Chen","year":"2018","unstructured":"Chen K, Cheng MP, Hammond SP, Einsele H, Marty FM. Antiviral prophylaxis for cytomegalovirus infection in allogeneic hematopoietic cell transplantation. Blood Adv. 2018;2:2159\u201375.","journal-title":"Blood Adv."},{"key":"1082_CR16","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1016\/S1473-3099(19)30107-0","volume":"19","author":"P Ljungman","year":"2019","unstructured":"Ljungman P, de la Camara R, Robin C, Crocchiolo R, Einsele H, Hill JA, et al. Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leuekmia (ECIL7). Lancet Infect Dis. 2019;19:e260\u201372.","journal-title":"Lancet Infect Dis."},{"key":"1082_CR17","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1016\/j.bbmt.2019.12.216","volume":"26","author":"D Zamora","year":"2020","unstructured":"Zamora D, Akoto B, Xie H, Kiener R, Edmison BC, Stevens-Ayers T, et al. Cytomegalovirus (CMV)-specific polyfunctional T-cell responses after letermovir (LET) prophylaxis in hematopoietic cell transplantation (HCT). Biol Blood Marrow Transplant. 2020;26:S68\u20139.","journal-title":"Biol Blood Marrow Transplant."},{"key":"1082_CR18","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","volume":"14","author":"L Luznik","year":"2008","unstructured":"Luznik L, O\u2019Donnell PV, Symons HJ, Chen AR, Leffell MS, Zaburak M, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantion cyclophosphamide. Biol Blood Marrow Transplant. 2008;14:641\u201350.","journal-title":"Biol Blood Marrow Transplant."},{"key":"1082_CR19","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.bbmt.2015.06.008","volume":"21","author":"J Sugita","year":"2015","unstructured":"Sugita J, Kawashima N, Fujisaki T, Kakihana K, Ota S, Matsuo K, et al. HLA-haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide after busulfan-containing reduced-intensity conditioning. Biol Blood Marrow Transplant. 2015;21:1646\u201352.","journal-title":"Biol Blood Marrow Transplant."},{"key":"1082_CR20","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.bbmt.2015.04.012","volume":"21","author":"K Ikegame","year":"2015","unstructured":"Ikegame K, Yoshida T, Yoshihara S, Daimon T, Shimizu H, Maeda Y, et al. Unmanipulated haploidentical reduced-intensity stem cell transplantation using fludarabine, busulfan, low-dose antithymocyte globulin, and steroids for patients in non-complete remission or at high risk of relapse: a prospective multicenter phase I\/II study in Japan. Biol Blood Marrow Transplant. 2015;21:1495\u2013505.","journal-title":"Biol Blood Marrow Transplant."},{"key":"1082_CR21","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1056\/NEJMoa1506002","volume":"374","author":"N Kroger","year":"2016","unstructured":"Kroger N, Solano C, Wolschke C, Bandini G, Patriarca F, Pini M, et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. N Engl J Med. 2016;374:43\u201353.","journal-title":"N Engl J Med."},{"key":"1082_CR22","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/s41409-018-0369-0","volume":"54","author":"H Yokoyama","year":"2019","unstructured":"Yokoyama H, Kanda J, Kato S, Kondo E, Maeda Y, Saji H, et al. Effects of HLA mismatch on cytomegalovirus reactivation in cord blood transplantation. Bone Marrow Transplant. 2019;54:1004\u201312.","journal-title":"Bone Marrow Transplant."},{"key":"1082_CR23","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.bbmt.2011.05.015","volume":"18","author":"M Mikulska","year":"2012","unstructured":"Mikulska M, Raiola AM, Bruzzi P, Varaldo R, Annunziata S, Lamparelli T, et al. CMV infection after transplant from cord blood compared to other alternative donors: the importance of donor-negative CMV serostatus. Biol Blood Marrow Transplant. 2012;18:92\u20139.","journal-title":"Biol Blood Marrow Transplant."},{"key":"1082_CR24","doi-asserted-by":"crossref","first-page":"e12629","DOI":"10.1111\/tid.12629","volume":"19","author":"M Slade","year":"2017","unstructured":"Slade M, Goldsmith S, Romee R, DiPersio JF, Dubberke ER, Westervelt P, et al. Epidemiology of infections following haploidentical peripheral blood hematopoietic cell transplantation. Transpl Infect Dis. 2017;19:e12629.","journal-title":"Transpl Infect Dis."},{"key":"1082_CR25","doi-asserted-by":"crossref","first-page":"e13096","DOI":"10.1111\/tid.13096","volume":"21","author":"CH Lin","year":"2019","unstructured":"Lin CH, Su YJ, Hsu CY, Wang PN, Teng CJ. Haploidentical allogeneic hematopoietic stem cell transplantation increases the risk for cytomegalovirus infection in adult patients with acute leukemia. Transpl Infect Dis. 2019;21:e13096.","journal-title":"Transpl Infect Dis."},{"key":"1082_CR26","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1399-3062.2011.00706.x","volume":"14","author":"B George","year":"2012","unstructured":"George B, Kerridge IH, Gilroy N, Huang G, Hertzberg MS, Bradstock KF, et al. A risk score for early cytomegalovirus reactivation after allogeneic stem cell transplantation identifies low-, intermediate-, and high-risk groups: reactivation risk is increased by graft-versus-host disease only in the intermediate-risk group. Transpl Infect Dis. 2012;14:141\u20138.","journal-title":"Transpl Infect Dis."},{"key":"1082_CR27","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.bbmt.2006.12.454","volume":"13","author":"T Matsumura","year":"2007","unstructured":"Matsumura T, Narimatsu H, Kami M, Yuji K, Kusumi E, Hori A, et al. Cytomegalovirus infections following umbilical cord blood transplantation using reduced intensity conditioning regimens for adult patients. Biol Blood Marrow Transplant. 2007;13:577\u201383.","journal-title":"Biol Blood Marrow Transplant."},{"key":"1082_CR28","doi-asserted-by":"crossref","first-page":"E143","DOI":"10.1002\/ajh.25438","volume":"94","author":"Y Sawayama","year":"2019","unstructured":"Sawayama Y, Itonaga H, Fukushima T, Nakano N, Fujiwara H, Utsunomiya A, et al. Cytomegalovirus reactivation is associated with increased mortality more than 100 days after allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia\/lymphoma. Am J Hematol. 2019;94:E143\u20136.","journal-title":"Am J Hematol."},{"key":"1082_CR29","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/sj.bmt.1703661","volume":"30","author":"Y Tanaka","year":"2002","unstructured":"Tanaka Y, Kanda Y, Kami M, Mori S, Hamaki T, Kusumi E, et al. Monitoring cytomegalovirus infection by antigenemia assay and two distinct plasma real-time PCR methods after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2002;30:315\u20139.","journal-title":"Bone Marrow Transplant."},{"key":"1082_CR30","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/sj.bmt.1703542","volume":"29","author":"T Mori","year":"2002","unstructured":"Mori T, Okamoto S, Watanabe R, Yajima T, Iwao Y, Yamazaki R, et al. Dose-adjusted preemptive therapy for cytomegalovirus disease based on real-time polymerase chain reaction after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2002;29:777\u201382.","journal-title":"Bone Marrow Transplant."},{"key":"1082_CR31","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/sj.bmt.1703513","volume":"29","author":"K Yakushiji","year":"2002","unstructured":"Yakushiji K, Gondo H, Kamezaki K, Shigematsu K, Hayashi S, Kuroiwa M, et al. Monitoring of cytomegalovirus reactivation after allogeneic stem cell transplantation: comparison of an antigenemia assay and quantitative realtime polymerase chain reaction. Bone Marrow Transplant. 2002;29:599\u2013606.","journal-title":"Bone Marrow Transplant."},{"key":"1082_CR32","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1086\/339329","volume":"34","author":"P Ljungman","year":"2002","unstructured":"Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis. 2002;34:1094\u20137.","journal-title":"Clin Infect Dis."},{"key":"1082_CR33","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Trasnplant. 2013;48:452\u20138.","journal-title":"Bone Marrow Trasnplant."},{"key":"1082_CR34","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1016\/j.bbmt.2010.05.009","volume":"16","author":"Y Mori","year":"2010","unstructured":"Mori Y, Miyamoto T, Nagafuji K, Kamezaki K, Yamamoto A, Saito N, et al. High incidence of human herpes virus 6-associated encephalitis\/myelitis following a second unrelated cord blood transplantation. Biol Blood Marrow Transplant. 2010;16:1596\u2013602.","journal-title":"Biol Blood Marrow Transplant."},{"key":"1082_CR35","doi-asserted-by":"crossref","first-page":"40","DOI":"10.21037\/sci.2017.05.03","volume":"4","author":"S Servais","year":"2017","unstructured":"Servais S, Hannon M, Peffault de Latour R, Socie G, Beguin Y. Reconstitution of adaptive immunity after umbilical cord blood transplantation: impact on infectious complications. Stem Cell Investig. 2017;4:40.","journal-title":"Stem Cell Investig."},{"key":"1082_CR36","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/10245332.2016.1231968","volume":"22","author":"S Kako","year":"2017","unstructured":"Kako S, Akahoshi Y, Harada N, Nakano H, Kameda K, Ugai T, et al. HLA-mismatched haploidentical transplantation using low-dose antithymocyte globulin (ATG: thymoglobulin). Hematology. 2017;22:129\u201335.","journal-title":"Hematology"},{"key":"1082_CR37","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00277-019-03865-x","volume":"99","author":"T Konishi","year":"2020","unstructured":"Konishi T, Doki N, Nagata A, Yamada Y, Takezaki T, Kaito S, et al. Unmanipulated haploidentical hematopoietic stem cell transplantation using very low-dose antithymocyte globulin and methylprednisolone in adults with relapsed\/refractory acute leukemia. Ann Hematol. 2020;99:147\u201355.","journal-title":"Ann Hematol."},{"key":"1082_CR38","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/bmt.2015.306","volume":"51","author":"CH Yan","year":"2016","unstructured":"Yan CH, Xu LP, Wang FR, Chen H, Han W, Wang Y, et al. Causes of mortality after haploidentical hematopoietic stem cell transplantation and the comparison with HLA-identical sibling hematopoietic stem cell transplantation. Bone Marrow Transplant. 2016;51:391\u20137.","journal-title":"Bone Marrow Transplant."},{"key":"1082_CR39","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s10875-011-9630-7","volume":"32","author":"YJ Chang","year":"2012","unstructured":"Chang YJ, Zhao XY, Huo MR, Xu LP, Liu DH, Liu KY, et al. Immune reconstitution following unmanipulated HLA-mismatched\/haploidentical transplantation compared with HLA-identical sibling transplantation. J Clin Immunol. 2012;32:268\u201380.","journal-title":"J Clin Immunol."},{"key":"1082_CR40","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.bbmt.2014.05.029","volume":"20","author":"AM Raiola","year":"2014","unstructured":"Raiola AM, Dominietto A, Di Grazia C, Lamparelli T, Gualandi F, Ibatici A, et al. Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts. Biol Blood Marrow Transplant. 2014;20:1573\u20139.","journal-title":"Biol Blood Marrow Transplant."},{"key":"1082_CR41","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1093\/cid\/ciz490","volume":"70","author":"P Ljungman","year":"2020","unstructured":"Ljungman P, Schmitt M, Marty FM, Maertens J, Chemaly RF, Kartsonis NA, et al. A mortality analysis of letermovir prophylaxis for cytomegalovirus (CMV) in CMV-seropositive recipients of allogeneic hematopoietic-cell transplantation. Clin Infect Dis. 2020;70:1525\u201333.","journal-title":"Clin Infect Dis."},{"key":"1082_CR42","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1182\/blood.V95.7.2240","volume":"95","author":"AE Broers","year":"2000","unstructured":"Broers AE, van Der Holt R, van Esser JW, Gratama JW, Henzen-Logmans S, Kuenen-Boumeester V, et al. Increased transplant-related morbidity and mortality in CMV- seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. Blood. 2000;95:2240\u20135.","journal-title":"Blood."},{"key":"1082_CR43","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.bbmt.2010.03.020","volume":"16","author":"N Cantoni","year":"2010","unstructured":"Cantoni N, Hirsch HH, Khanna N, Gerull S, Buser A, Bucher C, et al. Evidence for a bidirectional relationship between cytomegalovirus replication and acute graft-versus-host disease. Biol Blood Marrow Transplant. 2010;16:1309\u201314.","journal-title":"Biol Blood Marrow Transplant."}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41409-020-01082-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-020-01082-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-020-01082-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T05:29:37Z","timestamp":1697002177000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-020-01082-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,2]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["1082"],"URL":"https:\/\/doi.org\/10.1038\/s41409-020-01082-z","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,2]]},"assertion":[{"value":"13 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"KA received grants and honoraria from Kyowa Hakko Kirin Co., Ltd, Janssen Pharmaceutical K.K., Bristol-Myers Squibb Co., Ltd, Novartis Pharma K.K., Otsuka Pharmaceutical Co., Ltd, MSD Co., Ltd, Astellas Pharmaceutical Co., Ltd, Nippon Shinyaku Co., Ltd, Sumitomo Dainippon Pharmaceutical Co., Ltd, Celgene Co., Ltd, SymBio Pharmaceutical Co., Ltd, Daiichi Sankyo Pharmaceutical Co., Ltd, and Takeda Pharmaceutical Co., Ltd. KN and TM received honoraria from Bristol-Myers Squibb Co., Ltd, Otsuka Pharmaceutical Co., Ltd, MSD Co., Ltd, Astellas Pharmaceutical Co., Ltd, Astellas Amgen Pharmaceutical Co., Ltd, Celgene Co., Ltd, Abbvie Pharmaceutical Co., Ltd, Takeda Pharmaceutical Co. The other authors have no conflict of interests to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}